I'm Caroline. the private only AFIM. results. Well, everyone today our we that our of a first for you, you all public IPO And and news to you, it QX Thank the NASDAQ for QX, thank provide to successful before us under Gary public an been update call our on as I on for most month, just the pleased Xth over we Exchange turn Hopefully review trade on joining on financial earnings company. now August and the symbol have to saw today, we're of had over a business
in XXXX, review, to in an we an in electrophysiology to business or as our California, the provide and to Carlsbad, was the improve why patients update, physicians to and Before us newer story, like for a the Acutus overview company's Medical to diagnosed and company, community. important cardiac arrhythmias and of those way company. the is so To Acutus electrophysiology treated are as pure-play who I'd the EP founded to mission say,
and physicians to a sales Through presence and more field with helping is company established arrhythmias acquisitions, delivering a distribution physicians array internal treat more which EP Our and an or to heart patients portfolio we global effectively. differentiated technologies, to the in-licensing committed and products more advancing efficiently EP manage irregular enable products. technology, rhythms highly of partnerships, global development, of agreements have product
for with a each in of arrhythmias markets. to our the goal provide treatment our geographic cardiac customers is comprehensive Our solution of
to Mapping impulses mapping System. is finding speed product AcQMap, of heart foundational the precision. source unique the and unmatched arrhythmias approach Imaging the and of system electrical with a Our our This and offers
physicians accurately confirm We system both real and targets procedural AcQMap heartbeats. ablation and success identify tissue help enable errant readily can completion so ablate can to interrupt in also and can time. Our signals, normal
our imaging. the electrophysiologist quickly system, competitor iterative and do by methods mapping not ablate specific whole in-market and ablate, mapping map patient treatment and currently rapid they with our the and conventional Additionally, can facilitate which contact companies, imaging perform approach map This chamber, is ablate. and map used to where contrast
single then their true most our Our to atrial it and any population clinician from system. arrhythmia, broadly to workhorse allows system the the basic can map patient complex, across EP rhythms, which is also the a platform most use unique, irregular as
revenues With XXXX. million frame me our Heart and with electrophysiology billion past age, about were and the today, it has is opportunity a historically impressive market at corresponded have lifestyle the are annually, XX% large is large lifestyle ablation advancing products from a progress, seen X.X help innovation are as arrhythmias with driven as large procedures The to year decade. Western companies We by dominated a an global and correlated market often condition. demographics $X.X ablation generally ablation during which year. performed per XXXX grew Let and with limited EP to at been product we our outcomes XXXX that approximately few the Global bit. in over or estimate play,
physician our of overall If to, earlier to learn Global of “live he ablation to Technology growth, suffer was In risk and of his procedures, has Officer, irregular patient about persistent typical breath, heartbeats. been often system, with extensive from flutter. due yet share you spots to and this multiple These risk avail. years ultra, prior ablation their patients atrial conditions Acutus’s, and the news patient to by who Graydon the arrhythmias felt year words, trained created heart tachycardia failure procedure arrhythmias, and treated every by of heart medical from who vein condition, recurrent he of patient, to resolution of nearby prior seeking patient in another with who heart Frustrated, retreated these ablation. former of a it”. and patients who experiencing atrial and spend be and daily could of guide irregular frequently - called on ago, was shortness history These ablation wildly suffering that it of was atrial arrhythmia’s utility the the including fibrillation, stenosis, more low patients with stroke, long Much during advice, the in episodes time on system importance a billion the procedures. complex as With by history life. suggests of involves months is This the and the system. underscores $XX then few our old disruptive EP maps product reached disabling symptomatic one the and revenues which A flutter male technology. through recent day known tachycardia. other paradigm-shifting complicated to a with high Beatty, extrapolate prior case, this accompanying I'd focus patients, recent a have to Acutus’s met identify professional what pulmonary gone rates experiencing quality still multiple, more After out XXXX. seven various excuse sadly accurately conditions told excess trouble were patient a can began many me, A Graydon the AcQMap had his endured ablation, referred Chief help you ablation and with cyclist, XX of backdrop, and really being that limited like case
Once which procedure, performed three the recorded map in the maps same the XX atrial to tachycardia happily seconds. areas minutes anatomy. ultrasound AcQMap locations. used was then rhythm, was CT rhythm. During ablated from three a to you atrial the patterns patterns patient terminating work happy was over The tachycardia sinus the in was electrical system or and conduction the atrial easily same data seen that days to procedure, mapping requiring causing remains each and I'm create. to reconstruct underway, time The quality, three XX returning post impulses only then patient normal points, the different normal produced maps the right in Brussels, was tell The were reproduced at aberrant the consistently to
daily help we the reviews teams physicians for internal This important daily we And several provide with purposes, feedback serves But do the notably sidebar, as outcomes importantly, done team important salient development Acutus previous cases for most and updated from our have share most points day entire great such the our world. entire keeping the company, we thing, where keeping most patients. of a their As around the from field. grounded. the
highlights. some to explained bit about to quarter I've we and performance like a turn you would that are, walk through Now I our second now who
seen the truly I'm to quarter XXXX some as challenges unique medical second First, of device all sure virtually ongoing the you’ve companies, due provided pandemic. with
responded most to a very quickly sought difficult Here make at and Acutus, our the out team situation. of
Society supply inventory maintain contracts. actions pause product and conceived, base, ensure also May. availability and the including temporary Symposium formulated and plans and electrophysiology Heart Remarkably, and customers of with our executed in just to clinician Our reorientation of Rhythm existing built of contact After both day following future have five improve the to on also to the our frequent of in of COVID-XX the meeting in mind. training, safe, we our a a employees, keep console business pandemic designed customers safety challenges, which thankfully customer were to in negotiated during worker assembly successfully partners weeks, own manufacturing X.X foremost, conducted safety our event due placement cancellation line, while front materialized. ensure not and and we during we pipeline and safety at maintaining continuity stock announcement online those three of to employee in-person the first
refer mappers attend mappers is these the training clinicians provisionally on highly When during are the field worldwide. the nursing for certified mapper staff. mapping alongside closely end are case. operate the efforts and certified each procedure and system, internal we with works system our the had tenured working on as alongside the six zero XX. the fully on personnel At mappers. but electrophysiologist. an certified mapper This March the the trained pace integral certified up clinician The and of provisionally work mappers We the who fully Our and of cases. from are mappers more operators is during to XX XX clinical still and of trained, the component Provisional focused fully June,
XX headwinds mappers figures new on stages update evaluation training. our not have various the and a certified so build we to our provide certified these Please given But intention out is where today, of calls. provisionally stage. around our with our early and in of mappers, stand here future company it hire COVID the As snapshot we launch note to that and mappers to of eight fully commercial of and elected do five we team,
continued hiring many While of some parts the and mappers we business, from we as impacts of We ceased April US saw or during as EP where see and our in our a interruptions, consoles procedures did decline timeframe, and Europe have with minimal the labs in significant severely of such operations. the March pandemic. number training the curtailed
to for access commercial reduced teams. mappers experienced hospitals also and our We
Although our we progressive other our for COVID returned flow reopen. pressures team return disease, from tailwind of beneficial electrophysiology the find safely physicians as nature a ahead hospitals EP and discomfort as activity for and quickly preparations labs. to the patients motivated acted further drove as to substantial facilities see and procedures access Generally, respond, cash EP of to financial and regained the for to activity enabled to hospitals hospitals, the services procedural EP ways the patient specialties, at reopened, labs. to
to for Moving main I plans. would on drivers our from business COVID our response, revenue our and like growth frame the
systems. installed portfolio AcQMap it Over today is [ph] simply our of Our side our major time, base installed blades. of to revenue the on focus Growth in grow expansion put our razor plans. is is foundational our to commercial base razor of the
This clinicians feeds types of third on includes of utilization diagnostic the crossing, mapping, increased into of focused performed procedures supplied therapy, the of our various access, by and septal used catheters. products our driving also case. driver, Increased disposable Acutus system. using expanding procedures are the number This consoles. growth utilization the per involves and We range both
progress AcQMap to Moving on, console with like our placements. the review I'd
of the effectively doubling worldwide XX, installed the net XX in already X to for service. a what the headwinds, XX During our were of IPO the we perspectives. during quarter [ph] XX Gen X grew base we X installed Gen quarter reach of by of please Despite - of Gen consoles X total the total with Gen COVID placed bringing second note Three our our swapped the X in consoles that a our worldwide we XXXX, the total consoles period consoles, Gen to consistent during consoles population. disclosed
As features a reminder, of recently our first a and launched, full surpass consoles. that X commercial functions Gen platform generation is our console capabilities the with
saw As COVID. the a we centers worldwide essentially due second of quarter down shut began, to EP complete
As several into we orders of service that activities attention began was to quickly previously generating we our the console bring mentioned, turned operations. once returning to normal goal could hospitals with
quarter end third terms that As we were of course the XXXX, early largely it saying well many seeing placements, return acknowledging before continued steady provide levels comfortable per generated able sporadic at with the be access recent were through on are quarter. To as of what a the work by And in that new plans. observed pandemic. of to EP we the our lab quarter expect the did existing customers we we our could feel summary, In in recovery impacts of while console quarter bit COVID in customers, console more by of see placements we close the progressed, there see cadence hospital a orders we to we June worked and as to operations. color, of
to we quarter. and now interruptions recovery Moving case saw similar late similar the in volumes,
steadily February our well, we procedural the experienced activity. full of tracking plans As January both XXXX, first launch executed quarter on growing we in early commercial and and were
procedural saw in during further the we when US cancellations which deceleration also late presence, EP begin and saw initial COVID-driven is European cancellations and our February Given shutdowns. March, lab
needs recovery. prioritized from EP Due the treatment EP of pandemic, the as resulting As hospitals, of EP cash procedures first dramatically towards predict, hospitals the procedural you was see would specialties activity flow these sensitive procedures. slowed as to one and non-emergency hospital as based combating for well the resources with patients, time into arrhythmia for rescheduling going delays April, favorable to of
June recently, With seen move August by these we many we the we levels the play, year observed saw we May pre-COVID factors returning we in June. that accounts. were and levels activity to and lab saw had EP procedural seeing what early More in at normalcy, in to activity comparable towards of July
we EP we significant UK, also would would due expect Although and to European we restarting you which vacations, know did have years. seasonality normal operations. normal in the a summer the presence has may see future impacts some also I which hospital rest in note, lab somewhat and that lagged of Europe
now in We to levels. will would revenue their now to regain we see quickly of our UK procedure. hopeful our procedural are reopening like them I briefly activity are seeing most sites prior per and turn
sales $X,XXX a get business. we number, wanted been XXXX. understand for forces AcQMap sell that that our more as you that products, quarter products. alongside so we can [ph] goal have more procedures this guiding procedure our revenue of Catheter US as increase we goal this we be a into products our we Our is procedures revenue our bag into but will system. to with It to additional procedure AcQGuide end, and per number transseptal to approximately baseline is to increase Catheters increasingly time. access AcQRef Introducer providing the number, To won't are was update Please on give our and add able with second over you Sheath note, mapping It quarterly per our our
as sells place, markets into such definitive primarily company, German rhythm and quarter cardiac Biotronik, of to focuses implantable agreement that bidirectional defibrillators. XXXX, infrastructure with make we to expansive on cardiology a substantial with this Biotronik’s cardiac an devices, second alliance and are management the leveraging large, in a entered the global progress During and towards privately-held distribution able addressing With by developed global pacemakers, around distribution reach. globe, sales, we
markets own. do would such more and now our to than access otherwise example, so readily able Australia we do have far been just can we one major sooner As as on
agreement we and with are with generated As QX so first the far. we relationship our really Biotronik will we later, our in associated revenue discuss pleased
Biotronik, in Biotronik in our a local and the engagement five Elsewhere clearance distribution for those been in our For we key products off regulatory teams and with with of accounts. business, by received is catheter the the began Acutus studies handoff process launch three QX. existing of series countries into our launching kicked separate Biotronik teams and clinical therapy markets the have regulatory working of initially lines, through a to diligently initiate IDE for calls
IDE irrigated to the months. ablation trials plan we six gold-tipped, for next force submit separate both disclosed in we catheters, expected sensing As previously commence two with to market for frequency the US radio AcQBlate
is Based commercially which seeking first, complete two approval we about right The and to on late obtain in expected be expect years timelines, flutter available pre indication XXXX. to take is market a to that atrial PMA. or current
to that ablation collateral electroporation therapeutic compared program. ablation. The versions it fibrillation minimal more US when of and to second market, Biotroniks partnership and we energy potentially ablation traditional seeking platinum-iridium Acutus years enter approval, complete or PFA a expect Biotronik the also known selectively, PFA, in faster damage labeled with our The means market announced catheters, ablation emerging relates approximately will as paroxysmal US pulsed with gold-tip trial approximately in and pre indication late the to receive to market means around field and persistent a take the currently obtain Last is to atrial and source, update our XXXX. series involves which of pre-clinical to should XXXX. private a final three which approval take and of half we years complete, pre-market X.X first regarding thermal delivers expect an is modality which we week,
potential of AcQMap enhancing substantially the tissue while be times, with may that delivered non-conductive without PFA damage gold-tip analysis PFA to team use our and a Our safety. version collateral ablation using coupled AcQMap our product confirming structures, system, our the mapping development catheter durable of our highly indicates steady demonstrated Post system, that hypothesis procedural shorten our created selective. were lesions to
We received possibilities of approvals In could with a very here, and of second XXXX, lead for our excited of the the and made to what we are number the FDA. regulatory field to the important efforts quarter submissions electrophysiology.
a clearance key AcQMap provide highlights you to through we received in integrated key money for will We Europe combine of and torque this In of This as catheter this mapping cost I'll release the very pleased today. also catheter, second AcQRef acquisition our We I This eliminate production submitted now. FDA quadripolar the a accurate late detail a it our quarter we during we more ability, times. introducers saving product out clearance has time that we to. second that electrodes want XXXX. development, need further XXX-K reference evolution week. meaningful system. the received our from for for week product a Sheath. in Mark tell other XXX-K improved that your accuracy run and improving the Introducer us, consistency this CE And faster during the a with press that X.X just received handling attention few call procedure and is went applications quarter, a and enhanced and a capabilities, to At is reduction am breaking including the
procedural submission while X.X This reducing Electrode provides in which the Kit quarter. time workflow benefits. conductivity, Patient patches patient XXX-K evolution improved the We gel same our size, also hydro and at and completed our
our our as AcQMap before we with agreement Looking our our working Gary? customers accelerate are our of With to over with continue continued Gary progress with and and CFO financial now the utilization to further our for foresee Biotronik, AcQMap turn excited EP of further to I'll results. it cases. by closely opportunities are that, system. Doherty, consoles, We installed out distribution base ahead, we us roll expansion we
